Farmak has changed the name of the anti-glaucoma drug Timolol (active ingredient: Timolol maleate) to Oftimol.
In recent years the Farmak-manufactured glaucoma treatment drug with active ingredient Timolol maleate has become one of the market leaders among anti-glaucoma drugs in general and beta-adrenergic receptor antagonists in particular.
Yevhen Shlapak, Marketing Specialist at Farmak’s Department for Marketing of Ophthalmologic and Dermatologic Drugs: ‘Today, 25 drugs from 14 manufacturers of Timolol maleate monodrugs are marketed in Ukraine. The absence of original name in Farmak-manufactured Timolol maleate has complicated identification and separation of Farmak’s Timolol manufactured using state-of-the-art high-tech equipment according to ISO and GMP quality standards from other, non-branded Timolol maleate medications whose quality and production conditions often raise doubts among physicians. Therefore, branding of Farmak-manufactured Timolol maleate (which now will be marketed as Oftimol) will give physicians a confidence that the patient will receive glaucoma treatment using a drug that underwent the required studies, was tested by experience of many Ukrainian ophthalmologists and manufactured at state-of-the-art production facilities in compliance with the world quality standards’.
